Value through Innovation27 July 2016

What is a lay summary?

Clinical Study Results

  • Volasertib - Myelodysplastic Syndromes
    Clinical Study Number 1230.43
    Study Indication Myelodysplastic Syndromes
    Product Volasertib
    Generic Name Volasertib
    Lab Code BI 6727
    Clinical Phase I
    Study Title

    An open label, phase I trial of intravenous administration of volasertib as monotherapy and in combination with azacitidine in patients with myelodysplastic syndrome after hypomethylating agents treatment failure

    Study Document
    Trial statement 1230.43 english
    Trial synopsis 1230.43 english
  • Volasertib - Myelodysplastic Syndromes
    Clinical Study Number 1230.33
    Study Indication Myelodysplastic Syndromes
    Product Volasertib
    Generic Name Volasertib
    Lab Code BI 6727
    Clinical Phase I
    Study Title

    An open label Phase I dose escalation trial to investigate the maximum tolerated dose, safety, pharmacokinetics and efficacy of intravenous volasertib in combination with subcutaneous azacitidine in patients with previously untreated high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) and not candidates for hematopoietic stem cell transplant

    Study Document
    Trial statement 1230.33 english
    Trial synopsis 1230.33 english